The main country of operation and country of incorporation is the UK. Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market and is developing a pipeline of immunotherapies for the treatment of cancer based on its patented ImmunoBody®, Moditope® and AvidiMab™ platforms. The Company's mission is to develop therapeutic cancer vaccines that stimulate the patient's immune system to mount an active response to reject or kill the growing tumour.